Bharat Immunologicals & Biologicals Corporation Limited announced earnings results for the full year ended March 31, 2021. For the full year, the company announced total revenue was INR 951.665 million compared to INR 680.202 million a year ago. Net loss was INR 130.792 million compared to INR 102.113 million a year ago. Basic loss per share from continuing operations was INR 3.03 compared to INR 2.36 a year ago.